Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies



Rating:

Share or cite this content

Citations should be made in the following way:
S. Noorduyn (Mississauga, Canada), B. Lancaster (Mississauga, Canada), A. Gendron (Montreal, Canada), L. Mbuagbaw (Hamilton, Canada), E. Penz (Saskatoon, Canada). Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma. 892

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Phenotyping Mepolizumab EXacerbations in severe eosinophilic asthma (MEX) Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Late Breaking Abstract - Use of mepolizumab in bronchiectasis with underlying eosinophilic condition Source: International Congress 2018 – New methods for diagnosing and treating lung diseases Year: 2018 Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy. Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Late Breaking Abstract - Response to mepolizumab in patients with severe CRSwNP using EUFOREA 2021 criteria Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Identification of patients with COPD who benefit from benralizumab Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019 Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Asthma control in preschool and subsequent disease remission Source: International Congress 2019 – Asthma and the world Year: 2019 Late Breaking Abstract - Systemic IL-26 correlates with improved asthma control in children with allergic sensitization Source: International Congress 2018 – Molecular and cellular determinants of the developing lung Year: 2018 Late Breaking Abstract: Persistent effect of bronchial thermoplasty (BT) in severe asthma at two years Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Late Breaking Abstract - Shared genetic origins of obesity and poor ICS response in children with asthma Source: Virtual Congress 2021 – Lung disease burden and management Year: 2021 Late Breaking Abstract - Characteristics of T2-biomarker low severe asthma patients in the UK Severe Asthma Registry (UKSAR) Source: International Congress 2019 – Asthma epidemiology in the 21st century Year: 2019 Late Breaking Abstract - Efficacy of CSJ117 on allergen-induced asthmatic responses in mild atopic asthma patients Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights Year: 2020